Humacyte (NASDAQ:HUMA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Humacyte (NASDAQ:HUMA) from a sell rating to a hold rating in a research note released on Saturday.

HUMA has been the topic of a number of other reports. Barclays initiated coverage on shares of Humacyte in a report on Wednesday, August 27th. They set an “overweight” rating and a $3.50 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Humacyte in a report on Monday, December 8th. Benchmark reduced their price objective on Humacyte from $14.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. D. Boral Capital reissued a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research report on Thursday, November 20th. Finally, HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Humacyte in a research note on Monday, December 1st. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $8.29.

Humacyte Stock Down 9.9%

Shares of NASDAQ:HUMA opened at $1.18 on Friday. Humacyte has a 52 week low of $1.09 and a 52 week high of $6.77. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.90 and a current ratio of 1.62. The company has a market capitalization of $220.98 million, a PE ratio of -5.13 and a beta of 1.90. The company has a 50 day moving average price of $1.44 and a two-hundred day moving average price of $1.85.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. The business had revenue of $0.75 million for the quarter, compared to the consensus estimate of $0.92 million. Analysts forecast that Humacyte will post -1.27 earnings per share for the current year.

Institutional Investors Weigh In On Humacyte

Institutional investors have recently made changes to their positions in the stock. Monashee Investment Management LLC bought a new position in Humacyte in the first quarter valued at approximately $3,410,000. Polar Asset Management Partners Inc. acquired a new stake in shares of Humacyte in the 1st quarter valued at $852,000. Woodline Partners LP increased its stake in shares of Humacyte by 38.7% in the 1st quarter. Woodline Partners LP now owns 3,950,000 shares of the company’s stock valued at $6,735,000 after purchasing an additional 1,101,198 shares during the last quarter. Nuveen LLC acquired a new position in shares of Humacyte during the 1st quarter worth $502,000. Finally, CenterBook Partners LP lifted its position in shares of Humacyte by 141.1% during the 2nd quarter. CenterBook Partners LP now owns 3,430,255 shares of the company’s stock worth $7,169,000 after buying an additional 2,007,743 shares during the last quarter. 44.71% of the stock is currently owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.